Dupilumab Efficacy and Safety as an Add-On Therapy in Uncontrolled Asthma Patients: A Systematic Review
Asthma is a heterogeneous chronic inflammatory condition affecting the lung. Standard treatment, a high-dose inhaled corticosteroid (ICS) and long-acting bronchodilator (LABA), effectively manages asthma in most individuals. However, 5%-10% of individuals with asthma were ineffective with those tre...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universitas Nahdlatul Ulama Surabaya
2022-11-01
|
| Series: | Jurnal Ilmiah Kesehatan |
| Online Access: | https://journal2.unusa.ac.id/index.php/JHS/article/view/2788 |
| _version_ | 1811190917772607488 |
|---|---|
| author | Evelyn Evelyn Putra Brillian Djohan Fauna Herawati |
| author_facet | Evelyn Evelyn Putra Brillian Djohan Fauna Herawati |
| author_sort | Evelyn Evelyn |
| collection | DOAJ |
| description |
Asthma is a heterogeneous chronic inflammatory condition affecting the lung. Standard treatment, a high-dose inhaled corticosteroid (ICS) and long-acting bronchodilator (LABA), effectively manages asthma in most individuals. However, 5%-10% of individuals with asthma were ineffective with those treatments. Recent RCTs suggested that Dupilumab posed potential as an add-on therapy. This systematic review aims to support the efficacy (the annualized rate of severe asthma exacerbation and increase in FEV1) and the safety of Dupilumab as an add-on therapy in uncontrolled asthma patients. We used "(Asthma) AND (Dupilumab)" as keywords on PubMed and ScienceDirect. We included only RCT design studies comparing the efficacy and safety of Dupilumab with a placebo in uncontrolled asthma patients. The placebo was ICS and LABA or oral glucocorticoids. This paper included five RCTs with 3400 participants, and their quality was assessed using Critical Appraisal Tools Program (CASP) tools. We conducted a meta-analysis to calculate the pooled risk ratio (RR). In addition, we used Mantel-Haenszel with 95% confidence intervals for dichotomous data. Furthermore, we used a random-effects model to count for interstudy heterogeneity. Then, we processed data using Revman 5.4. Dupilumab as an add-on therapy significantly showed a consistent effect in lower the annualized rate of severe asthma exacerbation (RR= 0.46; 95% CI 0.36- 0.58; p=0.007) and increased FEV1 compared to placebo. In addition, the most common adverse effect of using Dupilumab were injection site reaction, upper respiratory tract infections, and eosinophilia. In conclusion, Dupilumab is safe and well-tolerated as moderate-to-severe uncontrolled asthma add-on therapy
|
| first_indexed | 2024-04-11T14:58:19Z |
| format | Article |
| id | doaj.art-7cab156be7a342d48a13a4a9e3212769 |
| institution | Directory Open Access Journal |
| issn | 1978-6743 2477-3948 |
| language | English |
| last_indexed | 2024-04-11T14:58:19Z |
| publishDate | 2022-11-01 |
| publisher | Universitas Nahdlatul Ulama Surabaya |
| record_format | Article |
| series | Jurnal Ilmiah Kesehatan |
| spelling | doaj.art-7cab156be7a342d48a13a4a9e32127692022-12-22T04:17:06ZengUniversitas Nahdlatul Ulama SurabayaJurnal Ilmiah Kesehatan1978-67432477-39482022-11-01150310.33086/jhs.v15i03.2788Dupilumab Efficacy and Safety as an Add-On Therapy in Uncontrolled Asthma Patients: A Systematic ReviewEvelyn Evelyn0Putra Brillian Djohan1Fauna Herawati2Magister Program of Clinical Pharmacy, Faculty of Pharmacy, Surabaya University, Surabaya, IndonesiaAtmajaya School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, IndonesiaDepartment of Clinical and Community Pharmacy, Faculty of Pharmacy, Surabaya University, Surabaya, Indonesia Asthma is a heterogeneous chronic inflammatory condition affecting the lung. Standard treatment, a high-dose inhaled corticosteroid (ICS) and long-acting bronchodilator (LABA), effectively manages asthma in most individuals. However, 5%-10% of individuals with asthma were ineffective with those treatments. Recent RCTs suggested that Dupilumab posed potential as an add-on therapy. This systematic review aims to support the efficacy (the annualized rate of severe asthma exacerbation and increase in FEV1) and the safety of Dupilumab as an add-on therapy in uncontrolled asthma patients. We used "(Asthma) AND (Dupilumab)" as keywords on PubMed and ScienceDirect. We included only RCT design studies comparing the efficacy and safety of Dupilumab with a placebo in uncontrolled asthma patients. The placebo was ICS and LABA or oral glucocorticoids. This paper included five RCTs with 3400 participants, and their quality was assessed using Critical Appraisal Tools Program (CASP) tools. We conducted a meta-analysis to calculate the pooled risk ratio (RR). In addition, we used Mantel-Haenszel with 95% confidence intervals for dichotomous data. Furthermore, we used a random-effects model to count for interstudy heterogeneity. Then, we processed data using Revman 5.4. Dupilumab as an add-on therapy significantly showed a consistent effect in lower the annualized rate of severe asthma exacerbation (RR= 0.46; 95% CI 0.36- 0.58; p=0.007) and increased FEV1 compared to placebo. In addition, the most common adverse effect of using Dupilumab were injection site reaction, upper respiratory tract infections, and eosinophilia. In conclusion, Dupilumab is safe and well-tolerated as moderate-to-severe uncontrolled asthma add-on therapy https://journal2.unusa.ac.id/index.php/JHS/article/view/2788 |
| spellingShingle | Evelyn Evelyn Putra Brillian Djohan Fauna Herawati Dupilumab Efficacy and Safety as an Add-On Therapy in Uncontrolled Asthma Patients: A Systematic Review Jurnal Ilmiah Kesehatan |
| title | Dupilumab Efficacy and Safety as an Add-On Therapy in Uncontrolled Asthma Patients: A Systematic Review |
| title_full | Dupilumab Efficacy and Safety as an Add-On Therapy in Uncontrolled Asthma Patients: A Systematic Review |
| title_fullStr | Dupilumab Efficacy and Safety as an Add-On Therapy in Uncontrolled Asthma Patients: A Systematic Review |
| title_full_unstemmed | Dupilumab Efficacy and Safety as an Add-On Therapy in Uncontrolled Asthma Patients: A Systematic Review |
| title_short | Dupilumab Efficacy and Safety as an Add-On Therapy in Uncontrolled Asthma Patients: A Systematic Review |
| title_sort | dupilumab efficacy and safety as an add on therapy in uncontrolled asthma patients a systematic review |
| url | https://journal2.unusa.ac.id/index.php/JHS/article/view/2788 |
| work_keys_str_mv | AT evelynevelyn dupilumabefficacyandsafetyasanaddontherapyinuncontrolledasthmapatientsasystematicreview AT putrabrilliandjohan dupilumabefficacyandsafetyasanaddontherapyinuncontrolledasthmapatientsasystematicreview AT faunaherawati dupilumabefficacyandsafetyasanaddontherapyinuncontrolledasthmapatientsasystematicreview |